Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 06 Oct 2022 for Global Blood Therapeutics, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Kim Smith-Whitley: trading record in brief
Kim Smith-Whitley (chief executive) discloses dealings in Global Blood Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 1 June 2022 to 5 October 2022, the count stands at 3 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The record was last updated on 6 October 2022 with a transaction in Global Blood Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Kim Smith-Whitley
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
5,980 sharesCommon StockSEC:0000899243-22-033151:0
2,208 sharesCommon StockSEC:0000899243-22-030478:0
6,040 sharesCommon StockSEC:0000899243-22-021008:0
3 of 3 declarations
